Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
FGF9 Biologics Sequence Review Report 2026: Fibroblast growth factor 9 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL1R2 Biologics Sequence Review Report 2026: Interleukin-1 receptor type 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL1R2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ACKR3 Biologics Sequence Review Report 2026: Atypical chemokine receptor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ACKR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCR2 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCR1 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL32 Biologics Sequence Review Report 2026: Interleukin-32 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL32 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD19 Biologics Sequence Review Report 2026: B-lymphocyte antigen CD19 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGA4 Biologics Sequence Review Report 2026: Integrin alpha-4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGAM Biologics Sequence Review Report 2026: Integrin alpha-M Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAM protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF7 Biologics Sequence Review Report 2026: Fibroblast growth factor 7 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL11 Biologics Sequence Review Report 2026: Interleukin-11 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL3 Biologics Sequence Review Report 2026: C-X-C motif chemokine 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCL3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
949
950
951
952
953
>>
2260
>